Editorial Note on the Review Process
====================================

[F1000 Faculty Reviews](http://f1000research.com/browse/f1000-faculty-reviews) are commissioned from members of the prestigious [F1000 Faculty](http://f1000.com/prime/thefaculty) and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

1.  Ana Barac, Medstar Washington Hospital Center, Medstar Heart and Vascular Institute, Washington, USA [^2]

2.  Edimar A Bocchi, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil [^3]

3.  Monica S Ávila, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil [^4]

Introduction
============

Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide ^[@ref-1]^. Regrettably, cardiovascular disease (CVD) has risen in the aftermath as one of the most devastating consequences of cancer therapies ^[@ref-2],\ [@ref-3]^, being most prevalent in adult survivors of breast cancer and hematological malignancies ^[@ref-1],\ [@ref-4],\ [@ref-5]^.

In this work, we define cancer therapeutics-induced cardiotoxicity (CTIC) as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies, such as mediastinal radiotherapy ^[@ref-6]^ and/or some chemotherapeutic agents ^[@ref-7]^. These incipient toxic changes (e.g. cardiomyocyte apoptosis, cardiac ion-channel alteration, endothelial damage, etc.) can further develop into complex cardiovascular conditions, such as heart failure (HF), valvular heart disease, coronary artery disease (CAD), pericardial disease, systemic and pulmonary hypertension, arrhythmias, and thromboembolic disease, among others ^[@ref-8],\ [@ref-9]^. Concomitant pre-existent cardiovascular risk factors have been shown to foment this pathogenesis ^[@ref-10]^.

Pathogenesis of cancer therapeutics-induced cardiotoxicity
==========================================================

Cardiotoxic chemotherapy
------------------------

Doxorubicin (and other agents in the anthracycline family) is the archetype chemotherapeutic leading to CTIC, historically called anthracycline-induced cardiotoxicity or anthracycline-induced cardiomyopathy (AIC) ^[@ref-11]^. The hallmark of this condition is a HF syndrome arising from dilated cardiomyopathy (DCM) ^[@ref-11]^; supraventricular and ventricular arrhythmias have also been described during anthracycline administration but seldom require intervention ^[@ref-12]^. Its prevalence has not been thoroughly studied owing to lack of a uniform definition, inconsistent diagnostic criteria, and underreporting; in modern times, it is thought to affect 17--23% of survivors of pediatric hematological malignancies ^[@ref-13]--\ [@ref-15]^ and accounts for 2.6% of all patients with non-ischemic cardiomyopathy undergoing cardiac transplantation ^[@ref-16]^.

In addition to anthracyclines, an increasing number of chemotherapeutic agents have been labeled as "cardiotoxic", with particular mechanisms of action that lead to distinctive cardiovascular effects, and in turn various degrees of frequency and severity (see [Table 1](#T1){ref-type="table"} for a list of the most important cardiotoxic chemotherapeutic agents currently available in the US) ^[@ref-7],\ [@ref-8],\ [@ref-17]^. Because historical cardiotoxicity was mediated by non-specific agents such as anthracycline and alkylating agents, it was believed that the novel "targeted therapeutics" (e.g. monoclonal antibodies, tyrosine kinase inhibitors, etc.) would provide fewer off-target adverse effects. However, an increasingly systematic evaluation and reporting of cardiovascular safety, along with a concomitant explosion of basic ^[@ref-18]^, translational ^[@ref-19]^, and clinical research in the area of CTIC ^[@ref-20]^, have progressively revealed that a large number of these targeted agents are mechanistically determined to cause cardiotoxicity ^[@ref-21]^. Based on the weight of the evidence, the US Food and Drug Administration has recently issued several cardiovascular box warnings for some of these agents, such as myocardial toxicity for anthracyclines, cardiomyopathy for ERBB2 inhibitors, QT prolongation and sudden cardiac death for certain tyrosine kinase inhibitors, and immune-mediated adverse reactions (i.e. myocarditis) for CTLA-4 inhibitors, among others (see [Table 1](#T1){ref-type="table"}) ^[@ref-17]^.

###### Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity.

Text in bold represents US Food and Drug Administration box warnings. 5-FU, 5-fluorouracil; ALK, anaplastic lymphoma kinase; CSF-1R, colony-stimulating factor 1 receptor; ECG, electrocardiogram; EGFR, epidermal growth factor receptor; FKBP, FK506-binding protein; FGFR, fibroblast growth factor receptor; FLT3, FMS-like tyrosine kinase 3; GIST, gastrointestinal stromal tumor; GVHD, graft-versus-host disease; LT3, Lymphotoxin 3; HDAC, histone deacetylase; HGFR, hepatocyte growth factor receptor; HIF-1, hypoxia-inducible factor-1; Ig, immunoglobulin; IGF-1R, insulin-like growth factor 1-receptor; IL, interleukin; LAK, lymphokine-activated killer; mTOR, mammalian target of rapamycin; NK, natural killer; PD-1, programmed death 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed death ligand 1; PNET, primitive neuroectodermal tumor; SCD, sudden cardiac death; TdP, Torsades de Pointes; TIL, tumor-infiltrating lymphocyte; VEGF; vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity                                                                                                                                                                                                                                       
  -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Anthracyclines                                                                   Doxorubicin                                                                             *Breast cancer, non-Hodgkin lymphoma, Burkitt*\                   Anthracyclines bind directly to DNA\                                      Acute myocarditis, cardiomyopathy,\
                                                                                                                                                                           *lymphoma, mantle cell lymphoma, Hodgkin*\                        (intercalation) and also inhibit DNA repair\                              heart failure, bradyarrhythmias and\
                                                                                                                                                                           *lymphoma, Waldenstrom macroglobulinemia,*\                       (via topoisomerase II inhibition), resulting\                             tachyarrhythmias, non-specific ST or\
                                                                                                                                                                           *acute lymphocytic leukemia, small cell lung cancer, multiple*\   in blockade of DNA and RNA synthesis\                                     T wave changes. **BOX WARNING:**\
                                                                                                                                                                           *myeloma, gastric cancer, bladder cancer, Wilms'*\                and fragmentation of DNA. Doxorubicin\                                    **MYOCARDIAL TOXICITY**
                                                                                                                                                                           *tumor, bone sarcoma, soft tissue sarcoma, thymoma,*\             is also a p53 inhibitor and powerful iron\                                
                                                                                                                                                                           *neuroblastoma, hepatoblastoma, endometrial cancer*               chelator; the iron--doxorubicin complex\                                  
                                                                                                                                                                                                                                             binds to DNA and cell membranes,\                                         
                                                                                                                                                                                                                                             producing free radicals that cleave the\                                  
                                                                                                                                                                                                                                             DNA and cell membranes.                                                   

  Daunorubicin                                                                     *Acute myelocytic leukemia, acute lymphocytic*\                                                                                                                                                                                     
                                                                                   *leukemia, Kaposi sarcoma, non-Hodgkin lymphoma*                                                                                                                                                                                    

  Idarubicin                                                                       *Acute promyelocytic leukemia, acute myelocytic*\                                                                                                                                                                                   
                                                                                   *leukemia*                                                                                                                                                                                                                          

  Epirubicin                                                                       *Breast cancer, soft tissue sarcoma, bone sarcoma,*\                                                                                                                                                                                
                                                                                   *gastric cancer, esophageal cancer*                                                                                                                                                                                                 

  Mitoxantrone                                                                     *Non-Hodgkin lymphoma, Hodgkin lymphoma,*\                                                                                                                                                                                          
                                                                                   *prostate cancer, breast cancer, acute promyelocytic*\                                                                                                                                                                              
                                                                                   *leukemia, acute myelocytic leukemia*                                                                                                                                                                                               

  Alkylating agents                                                                Cyclophosphamide                                                                        *Breast cancer, non-Hodgkin lymphoma, mantle cell*\               Alkylating agents prevent cell division by\                               Atrial tachyarrhythmias or\
                                                                                                                                                                           *lymphoma, follicular lymphoma, Burkitt lymphoma,*\               cross-linking DNA strands and binding\                                    bradyarrhythmias, capillary\
                                                                                                                                                                           *Hodgkin lymphoma, Waldenstrom macroglobulinemia,*\               with nucleic acids and other intracellular\                               leak syndrome, cardiac arrest,\
                                                                                                                                                                           *acute lymphocytic leukemia, small cell lung cancer,*\            structures, inhibiting protein synthesis and\                             cardiomyopathy, heart failure,\
                                                                                                                                                                           \                                                                 DNA synthesis, resulting in cell death.                                   cardiogenic shock, hemopericardium,\
                                                                                                                                                                           *lymphoma, AL amyloidosis, multiple myeloma, gastric*\                                                                                      hemorrhagic myocarditis.
                                                                                                                                                                           *cancer, esophageal cancer, soft tissue sarcoma,*\                                                                                          
                                                                                                                                                                           *Wilms' tumor, gestational trophoblastic tumor,*\                                                                                           
                                                                                                                                                                           *neuroblastoma, bone sarcoma, brain tumor, ovarian*\                                                                                        
                                                                                                                                                                           *cancer, thymoma*                                                                                                                           

  Ifosfamide                                                                       *Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt*\                                                                                                                                                                                  
                                                                                   *lymphoma, neuroblastoma, small cell lung cancer,*\                                                                                                                                                                                 
                                                                                   *penile cancer, testicular cancer, hepatoblastoma,*\                                                                                                                                                                                
                                                                                   *bone sarcoma, soft tissue sarcoma*                                                                                                                                                                                                 

  Mitomycin                                                                        *Gastric cancer, anal cancer, pancreatic cancer, lung*\                                                                                                                                                                             
                                                                                   *cancer, mesothelioma, bladder cancer, breast cancer*                                                                                                                                                                               

  Bleomycin                                                                        *Hodgkin lymphoma, testicular cancer, ovarian cancer*                                   Phlebitis, pericarditis, chest pain,\                                                                                                       
                                                                                                                                                                           myocardial ischemia                                                                                                                         

  Cisplatin                                                                        *Bladder cancer, ovarian cancer, testicular cancer,*\                                   Arrhythmias, myocardial ischemia and\                                                                                                       
                                                                                   *breast cancer, cervical cancer, endometrial cancer,*\                                  infarction, ischemic cardiomyopathy,\                                                                                                       
                                                                                   *esophageal cancer, gastric cancer, head and neck*\                                     Raynaud's phenomenon, hypertension,\                                                                                                        
                                                                                   *cancer, Hodgkin lymphoma, mesothelioma, non-*\                                         stroke                                                                                                                                      
                                                                                   *Hodgkin lymphoma, non-small cell lung cancer,*\                                                                                                                                                                                    
                                                                                   *osteosarcoma, penile cancer, small cell lung cancer*                                                                                                                                                                               

  Trabectedin                                                                      *Soft tissue sarcoma, ovarian cancer*                                                   Cardiomyopathy, heart failure, cardiac\                                                                                                     
                                                                                                                                                                           arrest, peripheral edema, pulmonary\                                                                                                        
                                                                                                                                                                           embolism                                                                                                                                    

  Antimetabolites                                                                  5-FU                                                                                    *Breast cancer, anal cancer, gastric cancer,*\                    Antimetabolites inhibit DNA polymerase,\                                  Angina pectoris, vasospasm, myocardial\
                                                                                                                                                                           *esophageal cancer, colorectal cancer, cervical*\                 interfering with DNA and, to a lesser\                                    infarction, non-specific ECG changes,\
                                                                                                                                                                           *cancer, bladder cancer, head and neck cancer,*\                  degree, RNA synthesis. Some agents also\                                  atrial and ventricular bradyarrhythmias\
                                                                                                                                                                           *pancreatic cancer*                                               inhibit ribonucleotide reductase, DNA\                                    and tachyarrhythmias, cardiomyopathy,\
                                                                                                                                                                                                                                             primase, and DNA ligase I.                                                heart failure, pericardial effusion,\
                                                                                                                                                                                                                                                                                                                       cerebrovascular accident, local\
                                                                                                                                                                                                                                                                                                                       thrombophlebitis, pericarditis

  Capecitabine                                                                     *Colorectal cancer, breast cancer, biliary cancer,*\                                                                                                                                                                                
                                                                                   *esophageal cancer, pancreatic cancer, gastric cancer*                                                                                                                                                                              

  Fludarabine                                                                      *Chronic lymphocytic leukemia, acute myeloid*\                                                                                                                                                                                      
                                                                                   *leukemia, hematopoietic stem cell transplant, non-*\                                                                                                                                                                               
                                                                                   *Hodgkin lymphoma, Waldenstrom macroglobulinemia*                                                                                                                                                                                   

  Cytarabine                                                                       *Acute myelocytic leukemia, acute promyelocytic*\                                                                                                                                                                                   
                                                                                   *leukemia, acute lymphocytic leukemia, chronic*\                                                                                                                                                                                    
                                                                                   *lymphocytic leukemia, primary central nervous*\                                                                                                                                                                                    
                                                                                   *system lymphoma, Hodgkin lymphoma, non-Hodgkin*\                                                                                                                                                                                   
                                                                                   *lymphoma, meningeal leukemia*                                                                                                                                                                                                      

  Anti-ERBB\                                                                       Trastuzumab                                                                             *Breast cancer and gastric cancer (ERBB2+)*                       Binds to ERBB1 (EGFR) or ERBB2 (HER-\                                     Cardiomyopathy, heart failure, peripheral\
  monoclonal\                                                                                                                                                                                                                                2), mediating antibody-dependent cellular\                                edema, hypertension, arrhythmias. **BOX**\
  antibodies                                                                                                                                                                                                                                 cytotoxicity of cells that overexpress EGFR\                              **WARNING: CARDIOMYOPATHY**
                                                                                                                                                                                                                                             or HER-2 proteins.                                                        

  Pertuzumab                                                                                                                                                                                                                                                                                                           

  Necitumumab                                                                      *Non-small cell lung cancer (ERBB1+)*                                                   Arrhythmias, venous and arterial\                                                                                                           
                                                                                                                                                                           thomboembolism, ischemia. **BOX**\                                                                                                          
                                                                                                                                                                           **WARNING: CARDIOPULMONARY**\                                                                                                               
                                                                                                                                                                           **ARREST**                                                                                                                                  

  Anti-VEGF\                                                                       Bevacizumab                                                                             *Non-small cell lung cancer, cervical cancer, ovarian*\           Binds to and neutralizes VEGF-A,\                                         Hypertension, cardiomyopathy, heart\
  monoclonal\                                                                                                                                                              *cancer, breast cancer, endometrial cancer, renal cell*\          preventing its association with the\                                      failure, peripheral edema, hypotension,\
  antibodies                                                                                                                                                               *cancer, glioblastoma, soft tissue sarcoma, colorectal*\          endothelial receptors VEGFR1 and\                                         venous and arterial thromboembolism,\
                                                                                                                                                                           *cancer*                                                          VEGFR2, inhibiting angiogenesis and\                                      syncope, pulmonary embolism
                                                                                                                                                                                                                                             thus retarding the growth of all tissues\                                 
                                                                                                                                                                                                                                             (including metastatic tissue).                                            

  Aflibercept                                                                      *Colorectal cancer*                                                                     Inhibits VEGFR1 and VEGFR2                                                                                                                  

  Ramucirumab                                                                      *Colorectal cancer, gastric cancer, non-small cell lung*\                               Inhibits VEGFR2                                                                                                                             
                                                                                   *cancer*                                                                                                                                                                                                                            

  Immune checkpoint\                                                               Ipilimumab                                                                              *Melanoma, small cell lung cancer*                                Human IgG1 that blocks CTLA-4, which\                                     Acute myocarditis, cardiogenic shock.\
  inhibitors\                                                                                                                                                                                                                                is a downregulator of T-cell activation\                                  **BOX WARNING: IMMUNE-MEDIATED**\
  (monoclonal\                                                                                                                                                                                                                               pathways, enhancing their activation and\                                 **ADVERSE REACTIONS (including**\
  antibodies)                                                                                                                                                                                                                                proliferation                                                             **autoimmune myocarditis)**

  Nivolumab                                                                        *Head and neck cancer, Hodgkin lymphoma,*\                                              Human IgG4 that inhibits PD-1, enhancing\                         Peripheral edema, acute myocarditis,\                                     
                                                                                   *melanoma, non-small cell lung cancer, renal cell*\                                     T-cell activation and proliferation. It\                          cardiogenic shock, pulmonary embolism                                     
                                                                                   *cancer, urothelial carcinoma, small cell lung cancer*                                  potentiates the effects of CTLA-4 inhibitors                                                                                                

  Pembrolizumab                                                                                                                                                                                                                                                                                                        

  Atezolizumab                                                                     *Non-small cell lung cancer, urothelial carcinoma*                                      Human IgG1 that inhibits PD-L1 and\                               Peripheral edema, venous\                                                 
                                                                                                                                                                           CD80, enhancing T-cell activation and\                            thromboembolism                                                           
                                                                                                                                                                           proliferation. It potentiates the effects of\                                                                                               
                                                                                                                                                                           CTLA-4 inhibitors                                                                                                                           

  Avelumab                                                                         *Merkel cell carcinoma, urothelial carcinoma*                                           Peripheral edema, hypertension                                                                                                              

  Durvalumab                                                                       *Urothelial carcinoma*                                                                  Peripheral edema, myocarditis                                                                                                               

  Multi-targeted\                                                                  Sunitinib                                                                               *Renal cell cancer, soft tissue sarcoma, GIST*                    Inhibits multiple receptor tyrosine kinases\                              Hypertension, QTc prolongation,\
  (VEGFR) tyrosine\                                                                                                                                                                                                                          (VEGFR1, VEGFR2, and VEGFR3 mainly;\                                      bradycardia, peripheral edema,\
  kinase inhibitors                                                                                                                                                                                                                          also inhibits PDGFRα/β; LT3; FLT3; CSF-\                                  cardiomyopathy, heart failure, chest pain,\
                                                                                                                                                                                                                                             1R; RET; FGFR-1/3; cKIT; IL-2R; Lck; c-\                                  venous and arterial thromboembolim,\
                                                                                                                                                                                                                                             Fms; RET/PTC; CRAF; BRAF), preventing\                                    ischemia, myocardial infarction,\
                                                                                                                                                                                                                                             tumor growth and angiogenesis.                                            arrhythmias. **BOX WARNING: QTc**\
                                                                                                                                                                                                                                                                                                                       **PROLONGATION, TdP, AND SCD**\
                                                                                                                                                                                                                                                                                                                       **(vandetanib)**

  Pazopanib                                                                        *Renal cell cancer, soft tissue sarcoma, thyroid cancer*                                                                                                                                                                            

  Sorafenib                                                                        *Renal cell cancer, hepatocellular cancer, soft tissue sarcoma, GIST, thyroid cancer*                                                                                                                                               

  Axitinib                                                                         *Renal cell cancer, thyroid cancer*                                                                                                                                                                                                 

  Lenvatinib                                                                       *Renal cell cancer, thyroid cancer*                                                                                                                                                                                                 

  Regorafenib                                                                      *Colorectal cancer, GIST, hepatocellular carcinoma*                                                                                                                                                                                 

  Vandetanib                                                                       *Thyroid cancer (medullary)*                                                                                                                                                                                                        

  Multi-targeted\                                                                  Imatinib                                                                                *Acute lymphocytic leukemia, acute myelocytic*\                   Inhibits multiple receptor tyrosine kinases\                              Edema (anasarca, ascites, pericardial\
  (BCR-ABL) tyrosine\                                                                                                                                                      *leukemia, GIST*                                                  (Bcr-Abl mainly; also VEGFRs, PDGFRβ;\                                    and pleural effusion, peripheral edema,\
  kinase inhibitors                                                                                                                                                                                                                          SRC; LCK; YES; FYN; cKIT; EPHA2,\                                         pulmonary edema, and superficial\
                                                                                                                                                                                                                                             among others), inducing apoptosis.                                        edema), hypertension, hypotension,\
                                                                                                                                                                                                                                                                                                                       chest pain, cardiomyopathy, heart failure,\
                                                                                                                                                                                                                                                                                                                       QTc prolongation, tachyarrhythmias\
                                                                                                                                                                                                                                                                                                                       and bradyarrhythmias, pulmonary\
                                                                                                                                                                                                                                                                                                                       hypertension, myocardial ischemia\
                                                                                                                                                                                                                                                                                                                       and infarction. **BOX WARNING: QTc**\
                                                                                                                                                                                                                                                                                                                       **PROLONGATION, TdP, AND SCD**\
                                                                                                                                                                                                                                                                                                                       **(nilotinib). BOX WARNING: HEART FAILURE; ARTERIAL AND VENOUS**\
                                                                                                                                                                                                                                                                                                                       **THROMBOEMBOLISM (ponatinib)**

  Dasatinib                                                                        *Acute lymphocytic leukemia, chronic myelocytic leukemia, GIST*                                                                                                                                                                     

  Nilotinib                                                                        *Chronic myelocytic leukemia, GIST*                                                                                                                                                                                                 

  Bosutinib                                                                        *Chronic myelocytic leukemia*                                                                                                                                                                                                       

  Ponatinib                                                                        *Acute lymphocytic leukemia, chronic myelocytic*\                                                                                                                                                                                   
                                                                                   *leukemia*                                                                                                                                                                                                                          

  Multi-targeted\                                                                  Brigatinib                                                                              *Non-small cell lung cancer (EML4-ALK)*                           Inhibits multiple receptor tyrosine kinases\                              Sinus bradycardia, hypertension,\
  (ALK) tyrosine\                                                                                                                                                                                                                            (ALK, HGFR, c-MET, ROS1, IGF-1R, FLT-3,\                                  QTc prolongation, edema, pulmonary\
  kinase inhibitors                                                                                                                                                                                                                          EGFR, etc.), blocking cell proliferation.                                 embolism, syncope

  Crizotinib                                                                                                                                                                                                                                                                                                           

  Ceritinib                                                                                                                                                                                                                                                                                                            

  Multi-targeted\                                                                  Cobimetinib                                                                             *Melanoma and non-small cell lung cancer (BRAF*\                  MEK1 and MEK2 inhibitors (BRAF\                                           Cardiomyopathy, hypertension
  (MEK) tyrosine\                                                                                                                                                          *V600E and V600K mutations)*                                      pathway), causing decreased proliferation,\                               
  kinase inhibitors                                                                                                                                                                                                                          cell cycle arrest and apoptosis. Some also\                               
                                                                                                                                                                                                                                             inhibit RAS, RAF, and ERK.                                                

  Trametinib                                                                                                                                                                                                                                                                                                           

  Vemurafenib                                                                      Peripheral edema, hypotension, atrial\                                                                                                                                                                                              
                                                                                   fibrillation, QTc prolongation, retinal vein\                                                                                                                                                                                       
                                                                                   occlusion, vasculitis                                                                                                                                                                                                               

  Multi-targeted\                                                                  Lapatinib                                                                               *Breast cancer (ERBB2+)*                                          Inhibits EGFR (ERBB1) and HER2\                                           Peripheral edema, cardiomyopathy, heart\
  (ERBB) tyrosine\                                                                                                                                                                                                                           (ERBB2), regulating cellular proliferation\                               failure, hypertension, arrhythmias
  kinase inhibitors                                                                                                                                                                                                                          and survival                                                              

  Osimertinib                                                                      *Non-small cell lung cancer (ERBB1 T790M mutation)*                                     Inhibits EGFR (ERBB1 T790M and L858R\                             Cardiomyopathy, QTc prolongation,\                                        
                                                                                                                                                                           mutations), regulating cellular proliferation\                    venous thromboembolism, stroke                                            
                                                                                                                                                                           and survival                                                                                                                                

  Proteasome\                                                                      Carfilzomib                                                                             *Multiple myeloma*                                                Inhibits the 20S proteasome, leading to cell cycle arrest and apoptosis   Hypotension, acute pulmonary\
  inhibitors                                                                                                                                                                                                                                                                                                           edema, cardiomyopathy, heart failure,\
                                                                                                                                                                                                                                                                                                                       cardiogenic shock, bradyarrhythmias\
                                                                                                                                                                                                                                                                                                                       and tachyarrhythmias, angina pectoris,\
                                                                                                                                                                                                                                                                                                                       cerebrovascular accident, venous\
                                                                                                                                                                                                                                                                                                                       thromboembolism, hemorrhagic stroke,\
                                                                                                                                                                                                                                                                                                                       myocardial infarction, pericardial\
                                                                                                                                                                                                                                                                                                                       effusion, pericarditis, peripheral edema,\
                                                                                                                                                                                                                                                                                                                       pulmonary embolism.

  Bortezomib                                                                       *AL amyloidosis, follicular lymphoma, mantle cell*\                                     Inhibits the 26S proteasome, leading to\                                                                                                    
                                                                                   *lymphoma, Waldenstrom macroglobulinemia, multiple*\                                    cell-cycle arrest, and apoptosis                                                                                                            
                                                                                   *myeloma*                                                                                                                                                                                                                           

  Antimicrotubule\                                                                 Vinblastine                                                                             *Hodgkin lymphoma, testicular cancer, bladder*\                   Binds to tubilin and inhibits microtubulin\                               Angina, hypotension, myocardial\
  agents                                                                                                                                                                   *cancer, melanoma, non-small cell lung cancer, soft*\             formation; it is specific of M and S phases.                              ischemia and infarction, Raynaud's\
                                                                                                                                                                           *tissue sarcoma*                                                                                                                            phenomenon, limb ischemia

  Paclitaxel                                                                       *Breast cancer, bladder cancer, cervical cancer,*\                                      Inhibits microtubule disassembly,\                                Edema, hypotension, arrhythmias,\                                         
                                                                                   *endometrial cancer, esophageal cancer, gastric*\                                       interfering with the late G2 mitotic phase,\                      hypertension, syncope, cardiomyopathy,\                                   
                                                                                   *cancer, head and neck cancer, non-small cell lung*\                                    and inhibits cell replication. In addition, it\                   heart failure, venous thrombosis                                          
                                                                                   *cancer, small cell lung cancer, testicular cancer, soft*\                              can distort mitotic spindles, resulting in the\                                                                                             
                                                                                   *tissue sarcoma, thymoma/thymic carcinoma, penile*\                                     breakage of chromosomes.                                                                                                                    
                                                                                   *cancer, ovarian cancer*                                                                                                                                                                                                            

  Docetaxel                                                                        *Breast cancer, bladder cancer, bone sarcoma,*\                                         Inhibits microtubule disassembly,\                                Hypotension, cardiomyopathy, heart\                                       
                                                                                   *esophageal cancer, gastric cancer, head and neck*\                                     interfering with the M mitotic phase, and\                        failure. **BOX WARNING: FLUID**\                                          
                                                                                   *cancer, non-small cell lung*\                                                          inhibits cell replication                                         **RETENTION (including pulmonary**\                                       
                                                                                   *cancer, small cell lung cancer, ovarian cancer, pancreatic cancer, prostate*\                                                                            **edema)**                                                                
                                                                                   *cancer, soft tissue sarcoma, uterine sarcoma*                                                                                                                                                                                      

  Eribulin                                                                         *Breast cancer, liposarcoma*                                                            Synthetic analogue of halichondrin B that\                        Peripheral edema, hypotension, QTc\                                       
                                                                                                                                                                           inhibits polymerization of tubulin.                               prolongation                                                              

  Ixabepilone                                                                      *Breast cancer*                                                                         Epothilone B analog, inhibits tubulin (G2/M\                      Peripheral edema, angina pectoris                                         
                                                                                                                                                                           phase inhibitor)                                                                                                                            

  Immunomodulators                                                                 IL-2                                                                                    *Melanoma, neuroblastoma, renal cell cancer*                      Promotes proliferation, differentiation, and\                             Capillary leak syndrome, acute\
                                                                                                                                                                                                                                             recruitment of T and B cells, NK cells,\                                  myocarditis, hypotension, peripheral\
                                                                                                                                                                                                                                             thymocytes, LAK cells, and TILs, causing\                                 edema, cardiomyopathy, heart failure,\
                                                                                                                                                                                                                                             subsequent interactions between the\                                      ventricular tachyarrhythmias, cardiac arrest, myocardial infarction. **BOX**\
                                                                                                                                                                                                                                             immune system and malignant cells.                                        **WARNING: CARDIOPULMONARY**\
                                                                                                                                                                                                                                                                                                                       **DISEASE, CAPILLARY LEAK**\
                                                                                                                                                                                                                                                                                                                       **SYNDROME (including**\
                                                                                                                                                                                                                                                                                                                       **supraventricular and ventricular**\
                                                                                                                                                                                                                                                                                                                       **arrhythmias and myocardial infarction)**

  Interferon                                                                       *Melanoma, renal cell cancer*                                                           Inhibits cellular growth, alters cellular\                        Chest pain, myocardial ischemia\                                          
                                                                                                                                                                           differentiation and cell surface antigen\                         and infarction, atrial and ventricular\                                   
                                                                                                                                                                           expression, interferes with oncogene\                             tachyarrhythmias, edema, hypertension,\                                   
                                                                                                                                                                           expression, increases phagocytic\                                 cardiomyopathy, heart failure. **BOX**\                                   
                                                                                                                                                                           activity of macrophages, and augments\                            **WARNING: ISCHEMIC DISORDERS**\                                          
                                                                                                                                                                           cytotoxicity of lymphocytes                                       **(including stroke and myocardial**\                                     
                                                                                                                                                                                                                                             **infarction)**                                                           

  Thalidomide                                                                      *AL amyloidosis, Waldenstrom macroglobulinemia,*\                                       Increases NK cell number and levels of\                           Edema, deep vein thrombosis,\                                             
                                                                                   *multiple myeloma*                                                                      IL-2 and interferon gamma. Also inhibits\                         hypotension, hypertension, chest pain,\                                   
                                                                                                                                                                           angiogenesis, increases cell-mediated\                            atrial tachyarrhythmias, myocardial\                                      
                                                                                                                                                                           cytotoxic effects, and alters the expression\                     infarction, pulmonary embolism, syncope,\                                 
                                                                                                                                                                           of cellular adhesion molecules.                                   stroke, angina pectoris, cardiomyopathy,\                                 
                                                                                                                                                                                                                                             heart failure, cardiac arrest, cardiogenic\                               
                                                                                                                                                                                                                                             shock, increased cardiac enzymes. **BOX**\                                
                                                                                                                                                                                                                                             **WARNING: ARTERIAL AND VENOUS**\                                         
                                                                                                                                                                                                                                             **THROMBOEMBOLISM**                                                       

  Lenalidomide                                                                     *Mantle cell lymphoma, multiple myeloma, chronic*\                                      Inhibits secretion of proinflammatory\                                                                                                      
                                                                                   *lymphocytic leukemia, myelodisplastic syndrome,*\                                      cytokines; enhances cell-mediated\                                                                                                          
                                                                                   *AL amyloidosis, renal cell cancer, non-Hodgkin*\                                       immunity by stimulating proliferation of\                                                                                                   
                                                                                   *lymphoma*                                                                              anti-CD3 stimulated T cells (resulting in\                                                                                                  
                                                                                                                                                                           increased IL-2 and interferon gamma\                                                                                                        
                                                                                                                                                                           secretion); inhibits trophic signals to\                                                                                                    
                                                                                                                                                                           angiogenic factors in cells.                                                                                                                

  mTOR inhibitors                                                                  Sirolimus                                                                               *GVHD, renal angiomyolipoma*                                      Reduces protein synthesis and cell\                                       Peripheral edema, hypertension,\
                                                                                                                                                                                                                                             proliferation by binding to FKBP-12 and\                                  angina pectoris, atrial fibrillation,\
                                                                                                                                                                                                                                             subsequently inhibiting mTOR activation,\                                 cardiomyopathy, heart failure, deep vein\
                                                                                                                                                                                                                                             halting the cell cycle at the G1 phase. Also\                             thrombosis, hypotension, pulmonary\
                                                                                                                                                                                                                                             reduces angiogenesis by inhibiting VEGF\                                  embolism, renal artery thrombosis,\
                                                                                                                                                                                                                                             and HIF-1 expression. Temsirolimus is the\                                syncope
                                                                                                                                                                                                                                             prodrug of sirolimus, the active metabolite.\                             
                                                                                                                                                                                                                                             Everolimus is a sirolimus derivative.                                     

  Everolimus                                                                       *Breast cancer, renal cell cancer, astrocytoma, PNET*                                                                                                                                                                               

  Temsirolimus                                                                     *Renal cell cancer*                                                                                                                                                                                                                 

  Differentiation\                                                                 Tretinoin (ATRA)                                                                        *Acute promyelocytic leukemia*                                    Binds to nuclear receptors, decreasing\                                   Peripheral and facial edema, arrythmias,\
  agents                                                                                                                                                                                                                                     proliferation and inducing differentiation of\                            pericardial effusion/tamponade,\
                                                                                                                                                                                                                                             primitive promyelocytes                                                   myocardial ischemia and infarction,\
                                                                                                                                                                                                                                                                                                                       hypertension, cardiomyopathy, stroke,\
                                                                                                                                                                                                                                                                                                                       myocarditis, pericarditis, retinoic acid\
                                                                                                                                                                                                                                                                                                                       syndrome

  Arsenic trioxide                                                                 Induces apoptosis of primitive\                                                         Tachycardia, QTc prolongation, angina,\                                                                                                     
                                                                                   promyelocytes via DNA fragmentation                                                     hypotension. **BOX WARNING: QTc**\                                                                                                          
                                                                                                                                                                           **PROLONGATION, TdP, AND SCD**                                                                                                              

  HDAC inhibitors                                                                  Vorinostat                                                                              *Cutaneous T-cell lymphoma*                                       Inhibits HDAC1, HDAC2, HDAC3, and\                                        Peripheral edema, QTc prolongation,\
                                                                                                                                                                                                                                             HDAC6, resulting in the accumulation\                                     hypotension, tachyarrhythmias,\
                                                                                                                                                                                                                                             of acetyl groups, which alters chromatin\                                 pulmonary embolism, hypertension.\
                                                                                                                                                                                                                                             structure and transcription factor\                                       **BOX WARNING: SEVERE FATAL**\
                                                                                                                                                                                                                                             activation, leading to cell growth arrest\                                **CARDIAC ISCHEMIC EVENTS AND**\
                                                                                                                                                                                                                                             and apoptosis                                                             **ARRHYTHMIAS (panobinostat)**

  Romidepsin                                                                       *Cutaneous and peripheral T-cell lymphoma*                                                                                                                                                                                          

  Panobinostat                                                                     *Multiple myeloma*                                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cardiotoxic radiotherapy
------------------------

The significant delay between exposure to mediastinal radiotherapy and manifestation of heart disease, reporting bias, and the frequent concomitant use of cardiotoxic chemotherapy precludes an accurate determination of the incidence of radiation-induced cardiotoxicity ^[@ref-8]^. Having said that, it is believed that cancer survivors who have undergone chest radiotherapy have a 23% increase in absolute risk of cardiovascular morbidity and mortality after 20 years ^[@ref-22]^. When considering the risk of radiotherapy-induced cardiomyopathy, for example, Hodgkin lymphoma survivors who received mediastinal radiotherapy have a fivefold increase after 30 years ^[@ref-23]^, whereas the greatest risk for breast cancer survivors belongs to those who received left-sided chest radiation and concomitant anthracycline chemotherapy ^[@ref-24]^. This laterality risk factor is likely related to the higher incidence of severe CAD in the mid and distal left anterior descending and distal diagonal arteries that is also present in this population, which could contribute to left ventricular (LV) dysfunction ^[@ref-25]^.

Myocardial injury induced by radiotherapy has the hallmark of increased interstitial myocardial fibrosis ^[@ref-6]^, which in turn leads to diastolic LV dysfunction ^[@ref-26]^ and subtle contractile impairment ^[@ref-27]^. These pathological changes may also account for the higher incidence of conduction abnormalities, cardiovascular autonomic dysfunction, impaired exercise performance, and overall mortality ^[@ref-28]^. Additionally, cardiac radiation is associated with complex stenotic and regurgitant valvular lesions ^[@ref-29]^, pericardial disease ^[@ref-6]^, and carotid artery disease ^[@ref-30]^, among other conditions.

Stages of cancer therapeutics-induced cardiotoxicity
====================================================

Patterned after an established classification of disease progression ^[@ref-31]^, we have divided CTIC into four distinct stages, i.e. A, B, C, and D (see [Figure 1](#f1){ref-type="fig"}). Stage A CTIC refers to cancer patients with cardiovascular health. Stage B CTIC designates cancer patients with high risk of developing CTIC. Risk factors for CTIC can be broadly divided into those pertaining to the patient and those pertaining to the cancer therapies implemented (see [Table 2](#T2){ref-type="table"}) ^[@ref-5],\ [@ref-30],\ [@ref-32],\ [@ref-33]^. Stage C CTIC denotes "incipient" cardiotoxicity; this is the early stages of the cardiotoxic process before it becomes clinically apparent. This stage is characterized by the appearance of abnormal biomarkers that precede the clearly defined diseased entities (e.g. QTc prolongation precedes Torsade de Pointes and sudden cardiac death, and sarcomeric protein or natriuretic peptide serum elevations precede LV dysfunction and overt heart failure, etc.). Finally, stage D CTIC refers to established cardiotoxicity, which is manifested by cardiovascular syndromes in early or late stages, that requires standard diagnostic modalities and medical and surgical therapies derived from expert consensus guidelines ^[@ref-8],\ [@ref-31],\ [@ref-34]--\ [@ref-36]^.
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###### Risk factors of cancer therapeutics-induced cardiotoxicity.

CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; LVEF, left ventricular ejection fraction; RT, radiotherapy; SCD, sudden cardiac death; US FDA, United States Food and Drug Administration.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Risk factors of cancer therapeutics-induced cardiotoxicity                                                                                                                                       
  ------------------------------------------------------------ ----------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------
  Patient                                                      Age                                                                                                                                 

  Sex                                                                                                                                                                                              

  Risk Factors of CVD                                          Health behaviors                                                  Smoking/tobacco use                                               

  Overweigth and obesity                                                                                                                                                                           

  Physical inactivity                                                                                                                                                                              

  Poor nutrition                                                                                                                                                                                   

  Health factors                                               Hypertension                                                                                                                        

  Diabetes mellitus                                                                                                                                                                                

  Hyperlipidemia                                                                                                                                                                                   

  Metabolic syndrome                                                                                                                                                                               

  Kidney disease                                                                                                                                                                                   

  Risk factors of SCD                                          QTc prolongation                                                                                                                    

  Electrolyte abnormalities                                                                                                                                                                        

  Proarrhythmic drugs                                                                                                                                                                              

  Pre-existent CVD                                             e.g. CAD, HF, arrhythmias, etc                                                                                                      

  Cancer therapies                                             Cardiotoxic\                                                      High-dose anthracycline therapy                                   e.g. doxorubicin ≥250 mg/m ^2^ or epirubicin ≥600 mg/m ^2^
                                                               chemotherapy                                                                                                                        

  Low-dose anthracycline or\                                   e.g. low normal LVEF (\<53%), two or more general CVD risk\                                                                         
  trastuzumab therapy in high-risk\                            factors, age 60 or over, established moderate to severe CVD                                                                         
  patients                                                                                                                                                                                         

  Low-dose anthracycline and\                                  e.g. doxorubicin \<250 mg/m ^2^ or epirubicin \<600 mg/m ^2^ +\                                                                     
  trastuzumab sequential therapy                               trastuzumab                                                                                                                         

  Other chemotherapy                                           e.g. US FDA box warning agents                                                                                                      

  Cardiotoxic\                                                 High-dose cardiac radiation\                                      e.g. cardiac RT ≥30 Gy or ≥2 Gy/day                               
  radiotherapy                                                 therapy                                                                                                                             

  Inability of cardiac avoidance                               e.g. anterior or left chest radiation, tumor in cardiac\                                                                            
                                                               proximity, lack of shielding, etc.                                                                                                  

  Combination of\                                              Low-dose anthracycline + low-\                                    e.g. doxorubicin \<250 mg/m ^2^ or epirubicin \<600 mg/m ^2^ +\   
  cardiotoxic cancer\                                          dose radiation therapy                                            cardiac RT \<30 Gy                                                
  therapies                                                                                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Levels of prevention
====================

Preventive strategies for CTIC can also be divided into four standard levels, i.e. primordial, primary, secondary, and tertiary, which correspond with the stages of CTIC; each level of prevention has a particular goal, focus, and means (see [Figure 1](#f1){ref-type="fig"}).

Primordial prevention is principally focused on the education of both patients and providers and on the implementation of general best practices to impede the emergence and development of risk factors for CTIC. This is being accomplished by the explosion of expert consensus guidelines in the last decade (see "expert consensus guidelines" below) as well as a growing presence of cardio-oncology programs in major oncology and cardiology scientific meetings. Moreover, there has been an increasing number of continuing medical education materials and public health education programs in this topic, all serving to raise awareness and educate on the cardiovascular effects of cancer therapies. Furthermore, the International Cardio-Oncology Society and the Canadian Cardiac Oncology Network have recently partnered in the writing of a cardio-oncology multidisciplinary training proposal to formally educate physicians in this developing field ^[@ref-37]^.

Primary prevention has the goal of impeding the emergence of CTIC. The diagnosis and control of modifiable risk factors (see [Table 2](#T2){ref-type="table"}) and the promotion of cardiovascular health in the cancer population are of utmost importance. In addition, the administration of cardioprotective therapies to selected patients with unavoidable moderate and high risk of CTIC is a means of primary prevention (see "cardioprotectants" below).

Secondary prevention is enforced once cardiac toxicity is incipient; early diagnosis and surveillance (see "blood biomarkers and diagnostic modalities" below), implementation of cardioprotective strategies, and administration of cardioprotective and basic therapies have the overarching goal to mitigate the progression of cardiotoxicity, restore cardiovascular health, and prevent complications. As in most health conditions, earlier diagnosis and treatment of CTIC seem to translate into improved outcomes ^[@ref-38]^. Inspired by the American Society of Clinical Oncology (ASCO) clinical practice guideline on the prevention and monitoring of cardiac dysfunction in survivors of adult cancers ^[@ref-5]^, as well as by other recent expert consensus guidelines that include recommendations on the prevention of CTIC ^[@ref-8],\ [@ref-32],\ [@ref-39],\ [@ref-40]^, we have constructed a table summarizing the general evidence-based recommendations for the prevention of cardiotoxicity before, during, and after cancer therapies (see [Table 3](#T3){ref-type="table"}).

###### Preventive strategies for cancer therapeutics-induced cardiotoxicity.

DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preventive strategies for cancer therapeutics-induced cardiotoxicity                           
  ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Before cardiotoxic cancer\                                                                     Prioritize non-cardiotoxic cancer therapies without compromising cancer-specific outcomes
  therapy                                                                                        

  Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)       

  Establish cardiovascular health (e.g. clinical examination, imaging, biomarkers)               

  Referral to specialist as appropriate                                                          

  During cardiotoxic cancer\                                                                     Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)
  therapy                                                                                        

  Evaluate and maintain cardiovascular health (e.g. clinical examination, imaging, biomarkers)   

  Referral to specialist as appropriate                                                          

  Cardiotoxic chemotherapy                                                                       Prioritize liposomal formulation and continuous infusion of doxorubicin

  Prioritize the use of dexrazoxane administration when considered\                              
  appropriate (e.g. high-dose anthracyclines)                                                    

  Discontinue chemotherapy when considered appropriate                                           

  Mediastinal radiotherapy                                                                       Prioritize lowest clinically effective radiation dose

  Deep-inspiration breath holding radiotherapy techniques                                        

  Intensity-modulated radiotherapy                                                               

  Discontinue radiotherapy when considered appropriate                                           

  After cardiotoxic cancer\                                                                      Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)
  therapy                                                                                        

  Monitor cardiovascular health (e.g. clinical examination, imaging, biomarkers)                 

  Referral to specialist as appropriate                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Lastly, once CTIC has progressed sufficiently to be manifest in cardiovascular syndromes (e.g. HF, arrhythmias, acute coronary syndromes, etc.), tertiary prevention aims to limit further progression and disability, and promote rehabilitation, by both basic and advanced cardiovascular therapeutics. The evaluation and management of these defined CTIC syndromes are similar to those encountered in non-cancer patients. There are several clinical practice guidelines for the evaluation and management of these conditions in the literature ^[@ref-31],\ [@ref-35],\ [@ref-36],\ [@ref-41],\ [@ref-42]^, and some specifically address the cancer population ^[@ref-8],\ [@ref-9]^; these tertiary prevention strategies will not be further detailed in this work.

Expert panel consensus guidelines
=================================

As mentioned above, the prevention of cardiotoxicity induced by cancer therapies has increasingly been the focus of several clinical cardiovascular and oncological societies, demonstrating the increasing relevance that this field has taken in the latest decade. In 2012, the European Society for Medical Oncology published a basic set of clinical practice guidelines for the prevention, monitoring, and management of CTIC ^[@ref-40]^. The American Society of Echocardiography and the European Society of Cardiovascular Imaging joined forces to create expert consensus guidelines for the multimodality imaging evaluation of cardiovascular complications of radiotherapy in adult patients in 2013 ^[@ref-30]^ as well as evaluation during and after cancer therapies in 2014 ^[@ref-43]^. These efforts aim to standardize the indications, acquisition protocols, definitions, limitations, and vendor variability for the different cardiac imaging modalities usually employed in the diagnosis and surveillance of CTIC. In 2016, the American Heart Association (AHA) released a comprehensive scientific statement describing the mechanism, magnitude, onset, and likelihood of direct myocardial toxicity of several anti-cancer medications, among other clinically approved drugs, "to assist healthcare providers in improving the quality of care for these patients" ^[@ref-7]^. In the same year, the Canadian Cardiovascular Society published a set of best practice guidelines for the management of cancer patients, focusing on the identification of the high-risk population and the detection and prevention of cardiotoxicity ^[@ref-39]^. This was followed by a position paper from the European Society of Cardiology summarizing the available evidence on the pathophysiology, prevention, diagnosis, therapeutic management, and long-term surveillance of the most common forms of cardiotoxicities induced by cancer therapies ^[@ref-8]^. Most recently, as mentioned above, the ASCO published a clinical practice guideline outlining general recommendations for the prevention of cardiac dysfunction in survivors of adult cancers ^[@ref-5]^. It was developed by an expert multidisciplinary physician panel using a systematic review (1996--2016) of 104 articles (meta-analyses, randomized clinical trials, and observational trials) and their clinical experience. Finally, the AHA has just published a scientific statement specifically and comprehensively dealing with the prevention of CVD in breast cancer patients, including that caused by cancer therapies ^[@ref-32]^.

Cardioprotectants
=================

The development and investigation of cardioprotective agents has been exponentially increasing since the early days of anthracycline cardiotoxicity. To date, only one cardioprotectant is approved for clinical use, i.e. dexrazoxane; many others have been tested in the clinical setting, and an even larger number are on preclinical stages of investigation (see [Table 4](#T4){ref-type="table"} for a succinct list of cardioprotective agents for CTIC that have been shown to be useful at different stages of research). The vast majority of cardioprotectants have been tested in the setting of anthracycline administration, either alone or in combination with other chemotherapeutic agents; a small number has been tested in trastuzumab-only administration.

###### Cardioprotectants in cancer therapeutics-induced cardiotoxicity.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PC-SOD, lecithinized human recombinant super oxide dismutase.

  Cardioprotectants in cancer therapeutics-induced cardiotoxicity                                                                                
  ----------------------------------------------------------------- ----------------------------------------- ---------------------------------- --------------------------------
  Clinical                                                          Antidotes                                 Dexrazoxane                        Lipshultz *et al*. ^[@ref-49]^
  N-acetylcysteine                                                  Myers *et al*. ^[@ref-54]^                                                   
  Beta-blockers                                                     Carvedilol                                Avila *et al*. ^[@ref-55]^         
  Nebivolol                                                         Kaya *et al*. ^[@ref-56]^                                                    
  Bisoprolol                                                        Pituskin *et al*. ^[@ref-57]^                                                
  Metoprolol                                                        Georgakopoulos *et al*. ^[@ref-58]^                                          
  ACEIs                                                             Enalapril                                 Cardinale *et al*. ^[@ref-59]^     
  Ramipril                                                          Jensen *et al*. ^[@ref-60]^                                                  
  Perindopril                                                       Pituskin *et al*. ^[@ref-57]^                                                
  ARBs                                                              Valsartan                                 Nakamae *et al*. ^[@ref-61]^       
  Candesartan                                                       Gulati *et al*. ^[@ref-62]^                                                  
  MRAs                                                              Spironolactone                            Akpek *et al*. ^[@ref-63]^         
  Statins                                                           Atorvastatin                              Acar *et al*. ^[@ref-64]^          
  Natural supplements                                               Melatonin                                 Lissoni *et al*. ^[@ref-65]^       
  Ubiquinone                                                        Iarussi *et al*. ^[@ref-66]^                                                 
  Vitamins C and E                                                  Wagdi *et al*. ^[@ref-67]^                                                   
  Levocarnitine                                                     Waldner *et al*. ^[@ref-68]^                                                 
  Preclinical                                                       ACEIs                                     Temocapril                         Tokudome *et al*. ^[@ref-69]^
  Delapril                                                          Maeda *et al*. ^[@ref-70]^                                                   
  Zofenopril                                                        Sacco *et al*. ^[@ref-71]^                                                   
  ARBs                                                              Losartan                                  Matouk *et al*. ^[@ref-72]^        
  Statins                                                           Fluvastatin                               Riad *et al*. ^[@ref-73]^          
  Biguanides                                                        Metformin                                 Kobashigawa *et al*. ^[@ref-74]^   
  Prostacyclins                                                     Iloprost                                  Neilan *et al*. ^[@ref-75]^        
  NSAIDs                                                            Meloxicam                                 Hassan *et al*. ^[@ref-76]^        
  Vasodilators                                                      Diazoxide                                 Hole *et al*. ^[@ref-77]^          
  Molsidomine                                                       Disli *et al*. ^[@ref-78]^                                                   
  Nicorandil                                                        Ahmed *et al*. ^[@ref-79]^                                                   
  Iron salts                                                        Ferric carboxymaltose                     Toblli *et al*. ^[@ref-80]^        
  Neuropeptides                                                     Ghrelin                                   Wang *et al*. ^[@ref-81]^          
  Natural antioxidants                                              Dihydromyricetin                          Zhu *et al*. ^[@ref-82]^           
  Hydroxytyrosol                                                    Granados-Principal *et al*. ^[@ref-83]^                                      
  Sesame oil                                                        Saleem *et al*. ^[@ref-84]^                                                  
  Sesamin                                                           Su *et al*. ^[@ref-85]^                                                      
  Salidroside                                                       Wang *et al*. ^[@ref-86]^                                                    
  Glutathione                                                       Mohamed *et al*. ^[@ref-87]^                                                 
  Quercetin                                                         Matouk *et al*. ^[@ref-72]^                                                  
  Isorhamnetin                                                      Sun *et al*. ^[@ref-88]^                                                     
  Cannabidiol                                                       Fouad *et al*. ^[@ref-89]^                                                   
  Resveratrol                                                       Dolinsky *et al*. ^[@ref-90]^                                                
  indole-3-carbinol                                                 Hajra e *t al*. ^[@ref-91]^                                                  
  α-Linolenic acid                                                  Yu *et al*. ^[@ref-92]^                                                      
  Synthetic antioxidants                                            Didox                                     Al-Abd *et al*. ^[@ref-93]^        
  Other                                                             Mdivi-1                                   Gharanei *et al*. ^[@ref-94]^      

Dexrazoxane
-----------

In the US, dexrazoxane is the only approved cardioprotective agent consistently shown to reduce the incidence or severity of AIC ^[@ref-44]^. It is recommended to be given intravenously, in a 10:1 ratio of dexrazoxane:doxorubicin (e.g. dexrazoxane 500 mg/m ^2^:doxorubicin 50 mg/m ^2^) in the context of normal renal function; cardiac monitoring should be continued during dexrazoxane therapy ^[@ref-17]^. Its use has been associated with statistically significant risk reductions for most doxorubicin-related cardiotoxic outcomes (other than survival) ^[@ref-45]^, without compromising its therapeutic efficacy, in both pediatric and adult populations ^[@ref-46]--\ [@ref-49]^. Although currently dexrazoxane use is strictly restricted to women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m ^2^ and need continued treatment to maintain tumor control ^[@ref-44],\ [@ref-50]^, its use in the treatment of other malignancies has been endorsed by expert guidelines ^[@ref-51]^. Having said that, dexrazoxane is not currently recommended for routine use with the initiation of doxorubicin therapy for either primary or metastatic disease ^[@ref-51]--\ [@ref-53]^. It needs to be noted that dexrazoxane was associated with a potential increased risk of acute myeloid leukemia, myelodysplastic syndrome, and second malignant neoplasms in a pediatric population with Hodgkin lymphoma in a single study a decade ago ^[@ref-95]^. Many later studies have not been able to reproduce these initial results ^[@ref-45],\ [@ref-96]--\ [@ref-98]^. Furthermore, a recent large clinical trial in a pediatric population corroborated these latter findings, suggesting that dexrazoxane was indeed cardioprotective, did not interfere with antitumor efficacy, did not result in an increased occurrence of toxicities, and had no association with a significant rise in second malignancies ^[@ref-99]^.

Cardiovascular pharmacotherapy
------------------------------

Given their consistent benefit in other cardiovascular conditions (e.g. HF and CAD), beta-blockers, angiotensin converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and HMG-CoA reductase inhibitors (statins) have been extensively studied in the clinical setting, in the context of both anthracycline and trastuzumab therapy, for the prevention of LV dysfunction.

Beta-blocker agents with antioxidant properties such as carvedilol ^[@ref-100]--\ [@ref-102]^ and nebivolol ^[@ref-56]^ have shown the most promising results in early small clinical trials investigating their cardioprotective effects. Regrettably, in the so far largest clinical trial of beta-blockers for the prevention of cardiotoxicity under contemporary anthracycline dosage, carvedilol monotherapy had no impact on the incidence of early onset of LV ejection fraction (LVEF) reduction when compared to placebo in a breast cancer population ^[@ref-55]^. Similarly, ACEI monotherapy with enalapril ^[@ref-59]^ and ramipril ^[@ref-60]^ has also been shown to be beneficial in early small clinical trials; however, the administration of enalapril monotherapy either before chemotherapy or during or after chemotherapy in selected patients with elevated serum troponin levels failed to have a significant impact on outcomes in the most recent multicenter clinical trial ^[@ref-103]^. As for ARBs, valsartan was shown to be beneficial in small clinical trials over a decade ago ^[@ref-61]^; however, the use of candesartan as a cardioprotectant has recently provided conflicting results in well-conducted randomized placebo-controlled clinical trials ^[@ref-104],\ [@ref-62]^. The cardioprotective effects of spironolactone monotherapy have also been promising in early small clinical settings ^[@ref-63]^, but data from larger randomized clinical trials are still lacking.

Several clinical trials have investigated the cardioprotective effects of combined neurohormonal inhibition, i.e. beta-blockers plus ACEIs/ARBs, as is recommended in the general population with HF ^[@ref-34]^. Over a decade ago, early initiation of combined beta-blockers and ACEIs was shown to provide benefit in a small population of established AIC, albeit the effect was thought to be mediated mainly by beta-blockers ^[@ref-105]^. Since then, the role of combined neurohormonal inhibition in cardioprotection has been repeatedly evaluated up to this day in the settings of anthracycline, trastuzumab, or sequential chemotherapy. In the only positive trial to date, the combination of enalapril and carvedilol was shown to prevent deterioration of LV function in adult patients with hematological malignancies undergoing anthracycline therapy ^[@ref-106]^. However, there are significant concerns regarding this trial, including lack of blinding and differing results based on the methods used to quantify LVEF, making it difficult to conclusively interpret ^[@ref-107]^. In other clinical settings, metoprolol has been tested in combination with enalapril ^[@ref-58]^ and with candesartan ^[@ref-62]^, with disappointing results. Similarly, the combination of bisoprolol and perindopril failed to prevent trastuzumab-induced LV remodeling in a modern cohort of ERBB-positive breast cancer patients ^[@ref-57]^. Finally, in the as-yet-unpublished work by Guglin *et al*. presented at the 2018 American College of Cardiology annual meeting, both lisinopril and carvedilol failed to prevent cardiotoxicity in breast cancer patients treated with trastuzumab monotherapy, whereas both drugs prevented cardiotoxicity in patients who received both anthracycline and trastuzumab sequential therapy ^[@ref-108]^.

The cardioprotective role of statins has also been evaluated in small retrospective and prospective analyses, both with non-specific statins ^[@ref-109],\ [@ref-110]^ and atorvastatin monotherapy ^[@ref-64]^, and was found to be beneficial. These findings are very promising but are yet to be corroborated in larger randomized placebo-controlled trials (simvastatin NCT02096588; atorvastatin NCT02674204).

Natural supplements
-------------------

Clinical cardioprotective data involving natural supplements are scarce but growing. Ubiquinone (coenzyme Q10) administration in children receiving anthracyclines was associated with a lesser degree of LV dysfunction and remodeling ^[@ref-66]^. N-acetylcysteine, administered either alone or with vitamins E and C, averted LV dysfunction from developing in patients receiving high-dose doxorubicin and/or radiotherapy, respectively ^[@ref-67],\ [@ref-54]^. Melatonin ^[@ref-65]^ and levocarnitine ^[@ref-68]^ have also been tested in the clinical setting with positive results. Larger randomized placebo-controlled trials are lacking as to draw firm conclusions relevant to the clinical practice.

Preclinical agents
------------------

Many other agents have been shown to ameliorate anthracycline cardiotoxicity in small animal models of CTIC. Clinically available agents such as losartan ^[@ref-72]^, fluvastatin ^[@ref-73]^, metformin ^[@ref-74]^, iloprost ^[@ref-75]^, and meloxicam ^[@ref-76]^ as well as other clinically unavailable ACEIs ^[@ref-69]--\ [@ref-71]^ have been shown to have cardioprotective results *in vivo*. Vasodilators ^[@ref-77]--\ [@ref-79]^, neuropeptides ^[@ref-81]^, and iron salts ^[@ref-80]^ have also been found to be useful. Finally, given that the pathogenesis of anthracyclines is in part related to increased oxidative stress ^[@ref-100]^, several natural antioxidants (e.g. sesamin ^[@ref-85]^ and sesame oil ^[@ref-84]^ and hydroxytyrosol ^[@ref-83]^, among others ^[@ref-82],\ [@ref-86]--\ [@ref-92]^) have been tested and shown various degrees of cardioprotective effects. Didox, a synthetic antioxidant, was also shown to significantly potentiate the cytotoxicity of doxorubicin in liver cancer cells while at the same time protecting the murine model from cardiotoxicity ^[@ref-93]^. Mdivi-1, a mitochondrial division/mitophagy inhibitor, was also shown to lessen AIC ^[@ref-94]^.

Other cardioprotective strategies
---------------------------------

Within a family of cardiotoxic agents, there are variations in terms of cardiac safety. For example, the use of pegylated liposomal doxorubicin has been associated with a lower incidence of CTIC and HF ^[@ref-111],\ [@ref-112]^. Similarly, epirubicin or mitoxantrone are also believed to cause less cardiotoxicity compared with doxorubicin ^[@ref-113]^. When considering the large family of multitargeted tyrosine kinase inhibitors, vandetanib, nilotinib, and ponatinib seem to possess the highest cardiotoxicity risk ^[@ref-17]^. The role of exercise therapy in the prevention of CTIC remains controversial because of conflicting results ^[@ref-114],\ [@ref-115]^.

In summary, with the exception of dexrazoxane, no conclusive recommendations can be made on the clinical use of cardioprotectants for either stage B or stage C CTIC ^[@ref-5]^.

Blood biomarkers
================

Blood biomarkers, in particular myocardial natriuretic peptides (i.e. NTproBNP and BNP) and sarcomeric proteins (i.e. troponin I and T), have been an integral part of the diagnostic and prognostic armamentarium in common cardiovascular conditions, such as HF and CAD. As it would seem natural, they have been progressively adopted in clinical practice to assist in the diagnosis or surveillance of patients with incipient and established CTIC, in particular LV dysfunction and HF (see [Table 5](#T5){ref-type="table"} for a list of various clinical and preclinical biomarkers shown to predict CTIC) ^[@ref-5]^.

###### Blood biomarkers in cancer therapeutics-induced cardiotoxicity.

ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; cMLC1, cardiac myosin light chain-1; cTnAAbs, cardiac troponin specific autoantibodies; cTnI, cardiac troponin I; cTnT, cardiac troponin T; GWAS, genome-wide association study; hs-CRP, high-sensitive C-reactive protein; hs-TnI, high-sensitive troponin I; GDF15, growth differentiation factor-15; GPBB, glycogen phosphorylase BB; IMA, ischemia modified albumin; MPO, myeloperoxidase; NTproBNP, amino-terminal pro B-type natriuretic peptide; PlGF, placental-derived growth factor; ROS, reactive oxygen species.

  Blood biomarkers in cancer therapeutics-induced cardiotoxicity                                                                          
  ---------------------------------------------------------------- ------------------------------------ --------------------------------- ---------------------------------
  Clinical                                                         Myocardial natriuretic peptides      NTproBNP                          De Iuliis *et al*. ^[@ref-119]^
  BNP                                                              Lenihan *et al*. ^[@ref-37]^                                           
  ANP                                                              Nousiainen *et al*. ^[@ref-120]^                                       
  Myocardial sarcomere proteins                                    cTnI                                 Cardinale *et al*. ^[@ref-117]^   
  cTnT                                                             Kilickap *et al*. ^[@ref-118]^                                         
  hs-cTnI                                                          Sawaya *et al*. ^[@ref-121]^                                           
  hs-cTnT                                                          Katsurada *et al*. ^[@ref-122]^                                        
  us-cTnI                                                          Ky *et al*. ^[@ref-123]^                                               
  Other biomarkers                                                 cTnAAbs                              Ylänen *et al*. ^[@ref-124]^      
  Hb                                                               Garrone *et al*. ^[@ref-125]^                                          
  hsCRP                                                            Onitilo *et al*. ^[@ref-126]^                                          
  MPO                                                              Ky *et al*. ^[@ref-123]^                                               
  PIGF                                                             Putt *et al*. ^[@ref-127]^                                             
  GDF15                                                            Arslan *et al*. ^[@ref-128]^                                           
  Arginine-NO metabolites                                          Finkelman *et al*. ^[@ref-129]^                                        
  GPBB                                                             Horacek *et al*. ^[@ref-130]^                                          
  ROS                                                              Mercuro *et al*. ^[@ref-131]^                                          
  IMA                                                              Ma *et al*. ^[@ref-132]^                                               
  Single nucleotide polymorphims (GWAS)                            rs2229774                            Aminkeng *et al*. ^[@ref-133]^    
  rs1786814                                                        Wang *et al*. ^[@ref-134]^                                             
  rs28714259                                                       Schneider *et al*. ^[@ref-135]^                                        
  Preclinical                                                      DNA                                  Doxorubcin DNA adducts            Hahm *et al*. ^[@ref-136]^
  Spp1, Fhl1, Timp1, Ccl7 and Reg3b                                Mori *et al*. ^[@ref-137]^                                             
  MicroRNA                                                         miR-34a                              Desai *et al*. ^[@ref-138]^       
  miR-34c                                                          Vacchi-Suzzi *et al*. ^[@ref-139]^                                     
  miR-146a                                                         Horie *et al*. ^[@ref-140]^                                            
  Proteins                                                         S100A1                               Eryilmaz *et al*. ^[@ref-141]^    
  cMLC1                                                            ElZarrad *et al*. ^[@ref-142]^                                         
  Cathepsin B                                                      Bao *et al*. ^[@ref-143]^                                              
  Proteomics pattern diagnostics                                                                        Petricoin *et al*. ^[@ref-144]^   
  Metabolomics pattern diagnostics                                                                      Li *et al*. ^[@ref-145]^          
  Transcriptome profiling                                                                               Todorova *et al*. ^[@ref-146]^    

Troponin I ^[@ref-59],\ [@ref-116],\ [@ref-117]^ and troponin T ^[@ref-118]^ have been shown to be clinically useful in several clinical trials of cardiotoxicity prediction. Modern, more-sensitive assays of troponin I and T (high-sensitivity and ultra-sensitivity) have also been shown to be clinically predictive of CTIC ^[@ref-121]--\ [@ref-123]^. Early studies have suggested that troponin I elevation predicted severity of CTIC ^[@ref-116],\ [@ref-117]^, and refractoriness to HF therapy in the case of trastuzumab-induced cardiomyopathy ^[@ref-117]^, but response to enalapril monotherapy in the case of AIC ^[@ref-59]^. However, in a recent large multicenter randomized clinical trial, these findings could not be corroborated ^[@ref-103]^. Interestingly, the presence of troponin-specific autoantibodies also predicted cardiac dysfunction by cardiac magnetic resonance (CMR) imaging in the absence of elevated traditional troponin levels ^[@ref-124]^. Myocardial natriuretic peptides, such as NTproBNP ^[@ref-119]^, BNP ^[@ref-147]^, and ANP ^[@ref-120]^, have also been shown to be clinically useful predictors of CTIC, albeit to a lesser extent.

Although the use of these blood biomarkers is currently recommended in the evaluation and surveillance of patients with CTIC ^[@ref-5],\ [@ref-8]^, their helpfulness remains disputed owing to inconsistent results in terms of sensitivity, accuracy, and reliability ^[@ref-148]^. Hence, various other alternative blood biomarkers have been studied in recent years, either alone or in combination, and shown also to be clinically predictive of CTIC, e.g. hsCRP ^[@ref-126]^, MPO ^[@ref-123]^, and arginine-NO metabolites (arginine, citrulline, ornithine, asymmetric dimethylarginine, symmetric dimethylarginine, and N-monomethylarginine) ^[@ref-129]^, among others ^[@ref-125],\ [@ref-127],\ [@ref-128],\ [@ref-130]--\ [@ref-132]^. Likewise, many other predictive biomarker strategies are currently being developed in the preclinical arena. Proteomics ^[@ref-144]^ and metabolomics ^[@ref-145]^ pattern diagnostics, as well as transcriptome profiling ^[@ref-146]^, have been shown to be useful in animal models of AIC as well as the detection of doxorubicin DNA adducts (HM-dUMP, 8-OH-dGMP, HM-dCMP, and Me-dCMP) ^[@ref-136]^ and other particular genes that are overexpressed during incipient cardiotoxicity ^[@ref-137]^. Cellular proteins such as S100A1 ^[@ref-141]^, cMLC1 ^[@ref-142]^, and cathepsin B ^[@ref-143]^ have also been shown to have predictive value. Some microRNAs (e.g. miR-34a ^[@ref-138]^, miR-34c ^[@ref-139]^, and miR-146a ^[@ref-140]^) have been shown to be useful in predicting CTIC in small animal models; however, a recent clinical trial involving miR-208a measurement in breast cancer patients failed to have a predictive impact ^[@ref-149]^.

Finally, research efforts to identify the genetic susceptibility of AIC have been increasing in the last decade, with the purpose of risk stratifying patients before they receive anthracycline chemotherapy. To date, three main single-nucleotide polymorphisms (SNPs: rs28714259 ^[@ref-135]^, rs1786814 ^[@ref-134]^, and rs2229774 ^[@ref-133]^) have been identified as being strongly associated with AIC by means of genome-wide association studies (GWAS) from pediatric and adult case-controlled clinical trial populations.

Diagnostic modalities
=====================

Non-blood diagnostic modalities are also an integral part of the evaluation of CVDs. For the purpose of early diagnosis and surveillance of CTIC, several imaging modalities have been studied since the late 1970s and shown to be of value (see [Table 6](#T6){ref-type="table"}). Historically, electrocardiography ^[@ref-150]^ was used to diagnose arrhythmias during anthracycline infusion, and radionuclide cineangiography (MUGA) ^[@ref-151],\ [@ref-152]^ was the first technique used to detect falls in LV systolic function in patients receiving anthracyclines ^[@ref-153]^. Although MUGA is still considered widely available and highly reproducible, it carries the main disadvantage of submitting cancer patients to small, but potentially significant, radiation exposure (5--10 mSv) ^[@ref-30],\ [@ref-43]^. Additionally, 2D-echocardiogram ^[@ref-154]^ and stress 2D-echocardiogram ^[@ref-155]^ have been shown to be beneficial in the serial evaluation of cancer patients undergoing cardiotoxic chemotherapies. Newer echocardiographic modalities, such as 3D-echocardiography ^[@ref-156]^ and LV global longitudinal strain (LVGLS) measurement by speckle-tracking echocardiography (STE) ^[@ref-157]^, have demonstrated superiority over 2D-echocardiography in terms of reproducibility and predictability, respectively. CMR is currently considered the gold standard modality in the assessment of LV and right ventricular volumes and function ^[@ref-158]^. Secondary modalities such as CMR strain imaging ^[@ref-159]^, T1 mapping ^[@ref-160]^, and extracellular volume fraction (ECV) ^[@ref-161]^ have also been clinically studied in recent years and found to be of great value in the assessment of subclinical cardiotoxicity. Among various non-imaging techniques, cardiopulmonary exercise testing was shown to detect abnormalities in peak oxygen consumption in cancer patients with apparently normal LV function ^[@ref-162]^, suggesting subclinical impairments of contractile reserve and chronotropic incompetence ^[@ref-28]^. Finally, many other imaging modalities are currently being studied in the preclinical arena to help detect incipient cardiotoxicity with high specificity and sensitivity. For example, 18F-labeled tetrapeptide caspase positron emission tomography (PET) is able to specifically diagnose doxorubicin-induced myocardial apoptosis in a murine model by detection of overexpressed myocardial caspase 3 resulting from anthracycline chemotherapy ^[@ref-163]^.

###### Diagnostic modalities in cancer therapeutics-induced cardiotoxicity.

2D, two-dimensional; 3D, three-dimensional; 99m Tc, technetium-99; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; ECV, extracellular volume fraction; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; MUGA, multigated acquisition; PET, positron emission tomography; RBC, red blood cells.

  Diagnostic modalities in cancer therapeutics-induced cardiotoxicity                                             
  --------------------------------------------------------------------- ----------------------------------------- ---------------------------------
  Established clinical                                                  ECG                                       Steinberg *et al*. ^[@ref-150]^
  MUGA (99m Tc-labeled RBC)                                             Schwartz *et al*. ^[@ref-151]^            
  Stress MUGA                                                           McKillop *et al*. ^[@ref-152]^            
  2D-echocardiography                                                   Thavendiranathan *et al*. ^[@ref-154]^    
  Stress 2D-echocardiography                                            Khouri *et al*. ^[@ref-155]^              
  CPET                                                                  Jones *et al*. ^[@ref-162]^               
  Novel clinical                                                        3D-echocardiography                       Walker *et al*. ^[@ref-156]^
  Speckle-tracking echocardiography (LVGLS)                             Negishi *et al*. ^[@ref-157]^             
  CMR                                                                   Armstrong *et al*. ^[@ref-158]^           
  CMR strain imaging                                                    Drafts *et al*. ^[@ref-159]^              
  CMR T1 mapping                                                        Lightfoot *et al*. ^[@ref-160]^           
  CMR ECV                                                               Jordan *et al*. ^[@ref-161]^              
  Preclinical                                                           PET (18F-labeled tetrapeptidic caspase)   Su *et al*. ^[@ref-163]^

According to current guidelines, echocardiography (ideally 3D-echocardiography) is the method of choice for the evaluation of patients before, during, and after cancer therapies ^[@ref-43]^. CMR and MUGA scan (in that order) should be utilized as alternative modalities whenever the echocardiographic image quality is deficient ^[@ref-5]^. When available, measurement of LVGLS by STE is also recommended as a complementary modality ^[@ref-5]^. CMR should also be considered for the evaluation of chronic "constrictive" pericarditis, when the diagnosis remains uncertain after a careful echocardiographic evaluation ^[@ref-43]^.

To date, there is little evidence to guide the indication, timing, and frequency of use of imaging modalities in patients undergoing cancer therapies. The ASCO expert consensus recommends an echocardiographic evaluation prior to the initiation of potentially cardiotoxic cancer therapies ^[@ref-5]^. Routine imaging surveillance in asymptomatic patients should be offered to patients based on the healthcare provider's perceived risk of CTIC, and the frequency of it needs to be individualized based on clinical judgment and patient circumstances ^[@ref-5]^. Subsequent to cardiotoxic cancer therapies, it is recommended that high-risk patients undergo a follow up LVEF evaluation between 6 and 12 months after completion of therapy ^[@ref-5]^.

Conclusions
===========

In this work, we have attempted to comprehensively and concisely survey the most relevant available literature pertaining to cardioprotection during cancer therapy. We have briefly summarized the pathophysiology of CTIC, describing the mechanisms of cardiotoxicity of various agents, and risk factors that promote this phenomenon. For didactic purposes, we have classified CTIC into four progressive stages, in which four levels of prevention are applied, each having a specific goal, focus, and means of prevention. We have subsequently reviewed the available data on cardioprotective agents, blood biomarkers, and imaging diagnostic modalities, which are the core of primary and secondary prevention strategies. Finally, we have provided general evidence-based preventive recommendations for CTIC following the most current expert consensus guidelines. The promotion of the cardiovascular health of cancer patients and cancer survivors is paramount, requiring the diligent and knowledgeable effort of a multidisciplinary team of healthcare providers; as in all medical disorders, prevention is better than cure.
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